Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine

type b capsular polysaccharide of Hib-vaccine is conjugated to the N. menningitidis outer membrane protein

Also Known As:

Hib-NOMP; PRP-OMPC; PedvaxHIB

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Bacterial Outer Membrane Proteins: 9
      - Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine: 8
  - Bacterial Proteins: 394
    - Bacterial Outer Membrane Proteins: 9
      - Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine: 8
Carbohydrates: 22023
- Polysaccharides: 15383
  - Bacterial Polysaccharides: 50
    - Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine: 8
Biological Factors: 2472
- Antigens: 143924
  - Bacterial Antigens: 807
    - Bacterial Polysaccharides: 50
      - Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine: 8
Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Bacterial Vaccines: 529
      - Haemophilus Vaccines: 37
        Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine: 8

Experts

1.	Halperin, Scott A: 3 articles (02/2011 - 11/2005)
2.	Hesley, Teresa M: 3 articles (02/2011 - 11/2005)
3.	Hoffenbach, Agnes: 3 articles (02/2011 - 11/2005)
4.	Radley, David: 3 articles (02/2011 - 11/2005)
5.	Silber, Jeffrey L: 3 articles (02/2011 - 11/2005)
6.	Zappacosta, Pamela S: 3 articles (02/2011 - 11/2005)
7.	Bhuyan, Prakash K: 2 articles (02/2011 - 04/2009)
8.	Boslego, John W: 2 articles (02/2011 - 04/2009)
9.	Diaz-Mitoma, Francisco: 2 articles (02/2011 - 04/2009)
10.	Martin, Jason C: 2 articles (02/2011 - 04/2009)

Related Diseases

1.	Tetanus 02/28/2001 - "A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity." 01/01/1993 - "In infants in whom diphtheria-tetanus-pertussis (DTP) vaccination is deferred because of medical contraindications, vaccination with the PRP-OMPC conjugate would appear to be preferable to HbOC because of the ability of the former to elicit antibody responses in the absence of diphtheria toxoid vaccination." 02/01/2011 - "Both PRP-OMPC formulations met prespecified acceptability criteria for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and poliovirus. " 02/28/2001 - "We evaluated the immunogenicity and reactogenicity of a new liquid pentavalent combination vaccine, which incorporates a diphtheria, tetanus and whole-cell pertussis vaccine (DTP) with Hib (PRP-OMPC) and hepatitis B vaccine (HB), in a series of three studies involving 2156 infants. " 04/28/2009 - "All PRP-OMPC formulations met prespecified acceptability criteria for postdose 3 immunogenicity for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and polio. "
2.	Diphtheria 02/28/2001 - "A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity." 01/01/1993 - "In infants in whom diphtheria-tetanus-pertussis (DTP) vaccination is deferred because of medical contraindications, vaccination with the PRP-OMPC conjugate would appear to be preferable to HbOC because of the ability of the former to elicit antibody responses in the absence of diphtheria toxoid vaccination." 02/01/2011 - "Both PRP-OMPC formulations met prespecified acceptability criteria for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and poliovirus. " 02/28/2001 - "We evaluated the immunogenicity and reactogenicity of a new liquid pentavalent combination vaccine, which incorporates a diphtheria, tetanus and whole-cell pertussis vaccine (DTP) with Hib (PRP-OMPC) and hepatitis B vaccine (HB), in a series of three studies involving 2156 infants. " 04/28/2009 - "All PRP-OMPC formulations met prespecified acceptability criteria for postdose 3 immunogenicity for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and polio. "
3.	Hepatitis B 02/28/2001 - "A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity."
4.	Whooping Cough (Pertussis) 01/01/1993 - "In infants in whom diphtheria-tetanus-pertussis (DTP) vaccination is deferred because of medical contraindications, vaccination with the PRP-OMPC conjugate would appear to be preferable to HbOC because of the ability of the former to elicit antibody responses in the absence of diphtheria toxoid vaccination." 02/01/2011 - "Both PRP-OMPC formulations met prespecified acceptability criteria for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and poliovirus. " 04/28/2009 - "All PRP-OMPC formulations met prespecified acceptability criteria for postdose 3 immunogenicity for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and polio. "
5.	Pain (Aches) 04/28/2009 - "Rates of adverse events (AEs) were similar among groups, with a trend for increased solicited injection-site reactions (pain, redness, swelling) with increasing PRP-OMPC and HBsAg concentration. " 11/01/2005 - "Injection-site pain, redness and swelling were reported by 46.7%, 46.7%, and 20.0% of the licensed vaccine recipients, 43.3%, 43.3%, and 26.7% of PRP-T/HBV10 recipients and 70.0%, 46.7%, and 46.7% of PRP-OMPC/HBV15 recipients, respectively. " 02/01/2011 - "Rates of adverse events (AEs) were similar among groups, with a trend for increased solicited vaccine-related injection-site reactions (pain, erythema, swelling) with increasing PRP-OMPC dose. "

Related Drugs and Biologics

1.	Vaccines
2.	Hepatitis B Vaccines (Hepatitis B Vaccine)
3.	Pertussis Vaccine
4.	Hepatitis B Surface Antigens (HBsAg)
5.	Antigens
6.	Diphtheria Toxoid (Vaccine, Diphtheria)
7.	COMVAX
8.	Recombivax HB
9.	Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (ActHIB)

Related Therapies and Procedures

1.	Injections
2.	Contraindications